Off-label use of rituximab for systemic lupus erythematosus in Europe.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rydén-Aulin Monica, Boumpas Dimitrios, Bultink Irene, Callejas Rubio Jose Luis, Caminal-Montero Luis, Castro Antoni, Colodro Ruiz Agustín, Doria Andrea, Dörner Thomas, Gonzalez-Echavarri Cristina, Gremese Elisa, Houssiau Frederic A, Huizinga Tom, Inanç Murat, Isenberg David, Iuliano Annamaria, Jacobsen Søren, Jimenéz-Alonso Juan, Kovács Lászlo, Mariette Xavier, Mosca Marta, Nived Ola, Oristrell Joaquim, Ramos-Casals Manuel, Rascón Javier, Ruiz-Irastorza Guillermo, Sáez-Comet Luis, Salvador Cervelló Gonzalo, Sebastiani Gian Domenico, Squatrito Danilo, Szücs Gabriella, Voskuyl Alexandre, van Vollenhoven Ronald
Аннотация
METHODS: Data on patients with SLE receiving RTX were taken from the International Registry for Biologics in SLE retrospective registry and complemented with data on patients with SLE treated with conventional therapy. For nationwide estimates of RTX use in patients with SLE, investigators were asked to provide data through case report forms (CRFs). Countries for which no data were submitted through CRFs, published literature and/or personal communication were used, and for European countries where no data were available, estimates were made on the assumption of similarities with neighbouring countries.
RESULTS: The estimated off-label use of RTX in Europe was 0.5%-1.5% of all patients with SLE. In comparison with patients with SLE on conventional therapy, patients treated with RTX had longer disease duration, higher disease activity and were more often treated with immunosuppressives. The most frequent organ manifestations for which either RTX or conventional therapy was initiated were lupus nephritis followed by musculoskeletal and haematological. The reason for treatment was, besides disease control, corticosteroid-sparing for patients treated with conventional therapy.
CONCLUSIONS: RTX use for SLE in Europe is restrictive and appears to be used as a last resort in patients for whom other reasonable options have been exhausted.